Drug Trial News

RSS

Experimental intranasal influenza vaccine produces durable immune response

An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.

3 Feb 2021

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Researchers at Chicago University have developed an innovative new anti-SARS-CoV-2 therapy called “Nanotraps” – a family of nano-enabled virus-trapping particles – which have shown positive results in vitro, in vivo, and in human ex vivo trials.

3 Feb 2021

IONICON analyzers at the forefront of COVID-19 testing research

COVID-19 breath detection is studied around the globe using PTR-TOFMS.

From Ionicon Analytik Ges.m.b.H. 3 Feb 2021

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

Researchers seeking to develop on-demand and behaviorally congruent HIV prevention options for people who practice anal sex are reporting the results of three early phase clinical trials of rectal microbicides at this week's HIV Research for Prevention (HIV R4P) Virtual Conference.

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19.

2 Feb 2021

Study shows safety and effectiveness of two recommended ICU sedatives

Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.

2 Feb 2021

Albumin: The Natural Choice for Diagnostic Tests

The availability of established diagnostic kits has enabled researchers to plug-and-play in the design of COVID-19 diagnostics. Such technologies took decades to optimize, but they are now playing an important role in identifying and managing the spread of COVID-19. Recombumin® provides an enhanced solution as part of this toolbox for dealing with this disease

From Albumedix Ltd. 2 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

Inhaled single dose vaccine creates antibodies and prevents infection in rhesus macaques

Now, a new preprint research paper describes a chimpanzee adenovirus-vectored vaccine that, when administered intranasally in rhesus macaques, led to a robust immune response and demonstrated protection against infection by the virus that causes COVID-19, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The preprint is published on the bioRxiv server.

1 Feb 2021

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

31 Jan 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

New results challenge the current understanding of medulloblastoma

Scientists at St. Jude Children's Research Hospital and their colleagues have published a detailed account of SJMB03, a clinical trial for pediatric patients with medulloblastoma.

28 Jan 2021

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

Hybrid closed-loop insulin therapy improves glycemic control in adolescents, young adults

Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. These outcomes, derived from the International Diabetes Closed-Loop (iDCL) Trial, are reported in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT).

27 Jan 2021

Moderna vaccine fully neutralizes new SARS-CoV-2 variants, study shows

Researchers in the United States have conducted a study showing that Moderna’s mRNA-1273 vaccine neutralizes all circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tested to date.

26 Jan 2021

Recombinant SARS-CoV-2 protein vaccine less immunogenic but more antigenic than expected

Now, a new preprint research paper posted to the medRxiv server presents preliminary results of a stabilized SARS-CoV-2 pre-fusion spike protein vaccine expressed in a baculovirus system (CoV2 preS dTM), with two different adjuvant formulations.

26 Jan 2021

COVID-19 diagnostic tests remain able to detect all published virus strains

Paris, France and Camberley, UK – 21 December 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the detection of a new variant of COVID-19 by the UK’s COVID19 Genomics UK consortium, known as VUI-202012/01, the Company has carried out a detailed analysis of the mutations in this new variant and in all published COVID-19 strains to fully assess the reliability of its existing diagnostic tests.

From AFSBio 25 Jan 2021

Previous
1
...
65
66
67
68
69
70
71
...
1149
Next

Drug Trial News

Experimental intranasal influenza vaccine produces durable immune response

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

IONICON analyzers at the forefront of COVID-19 testing research

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

Study shows safety and effectiveness of two recommended ICU sedatives

Albumin: The Natural Choice for Diagnostic Tests

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

Inhaled single dose vaccine creates antibodies and prevents infection in rhesus macaques

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

New results challenge the current understanding of medulloblastoma

What do we know about the SARS-CoV-2 vaccines so far?

Hybrid closed-loop insulin therapy improves glycemic control in adolescents, young adults

Moderna vaccine fully neutralizes new SARS-CoV-2 variants, study shows

Recombinant SARS-CoV-2 protein vaccine less immunogenic but more antigenic than expected

COVID-19 diagnostic tests remain able to detect all published virus strains

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News